These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 24667968)
41. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801 [TBL] [Abstract][Full Text] [Related]
42. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification. Nakazawa A Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257 [TBL] [Abstract][Full Text] [Related]
43. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660 [TBL] [Abstract][Full Text] [Related]
44. MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. Zormpas-Petridis K; Jerome NP; Blackledge MD; Carceller F; Poon E; Clarke M; McErlean CM; Barone G; Koers A; Vaidya SJ; Marshall LV; Pearson ADJ; Moreno L; Anderson J; Sebire N; McHugh K; Koh DM; Yuan Y; Chesler L; Robinson SP; Jamin Y Cancer Res; 2019 Jun; 79(11):2978-2991. PubMed ID: 30877107 [TBL] [Abstract][Full Text] [Related]
45. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells. Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739 [TBL] [Abstract][Full Text] [Related]
46. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Yi B; Yang J; Wang L Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393 [TBL] [Abstract][Full Text] [Related]
48. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment. Mazot P; Cazes A; Dingli F; Degoutin J; Irinopoulou T; Boutterin MC; Lombard B; Loew D; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M PLoS One; 2012; 7(3):e33581. PubMed ID: 22479414 [TBL] [Abstract][Full Text] [Related]
49. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749 [TBL] [Abstract][Full Text] [Related]
50. Frequency and Prognostic Impact of Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544 [TBL] [Abstract][Full Text] [Related]
51. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861 [TBL] [Abstract][Full Text] [Related]
52. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566 [TBL] [Abstract][Full Text] [Related]
53. Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. Almeida GS; Panek R; Hallsworth A; Webber H; Papaevangelou E; Boult JK; Jamin Y; Chesler L; Robinson SP Br J Cancer; 2017 Sep; 117(6):791-800. PubMed ID: 28787429 [TBL] [Abstract][Full Text] [Related]
54. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816 [TBL] [Abstract][Full Text] [Related]
55. The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development. Higashi M; Sakai K; Fumino S; Aoi S; Furukawa T; Tajiri T Surg Today; 2019 Sep; 49(9):721-727. PubMed ID: 30848386 [TBL] [Abstract][Full Text] [Related]